As government and industry leaders look to rein in the cost of healthcare, The Hill is convening a forward-looking conversation on biosimilar drugs and how they could affect healthcare access and affordability. Currently, two biosimilar drugs are poised to enter the U.S. market. Tune in to explore the potential cost savings of biosimilars, FDA approval processes for new medicines, and the state of the industry worldwide.
Follow the conversation online at @TheHillEvents and using #RxInnovation.
8:30 AM – Opening Remarks by Bob Cusack, The Hill
8:35 AM – Keynote Remarks by Senator Richard Blumenthal (D-CT)
8:55 AM – Industry perspectives provided by Dr. Steven Miller, Senior Vice President & Chief Medical Officer at Express Scripts. Moderated by Nielsen Hobbs, “The Pink Sheet”
9:00 AM – Discussion on patient access and affordability with Dan Durham, Executive Vice President for Policy & Regulatory Affairs at AHIP, Lori Reilly, Executive Vice President for Policy & Research at PhRMA, and Matt Salo, Executive Director for the National Association of Medicaid Directors. Moderated by Benjamin Goad and Elise Viebeck, The Hill
9:40 AM – Discussion on FDA approval processes for new drugs with Sally Howard, Deputy Commissioner for Policy, Planning & Legislation at the FDA, and David Gaugh, Senior Vice President for Sciences & Regulatory Affairs at GPhA. Moderated by Benjamin Goad, The Hill.
10:00 AM – Program concludes.
*Please note: Program is listed in Eastern Time. All times are approximate.